Clinical practice guidelines for congenital hypothyroidism in Korean children and adolescents: 2025
- Journal
- Annals of pediatric endocrinology & metabolism (Q1)
- Published
- 17 September 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Ji Hyun Kim, Aram Yang, Inhyuk Jung, Yonghee Hong, Eungu Kang, Jisun Park, et al.
- PMID
- 42767638
- DOI
- 10.6065/apem.2652002.001
Why clinicians should know about it
- Picked for Neonatology (top studies of the week, 27 September 2026): Guidelines for congenital hypothyroidism, unrelated to neonatal respiratory care
Abstract
Congenital hypothyroidism remains one of the most preventable causes of neurodevelopmental impairment. Population-based newborn screening has substantially improved outcomes; however, optimal practice requires appropriate timing of screening, special attention to high-risk subgroups, prompt initiation of levothyroxine, and structured long-term follow-up including re-evaluation for transient disease, transition to adult care, genetic evaluation, and monitoring of neurodevelopment and health-related quality of life. This review summarizes the 2025 Korean clinical practice guideline in 10 key questions and 28 recommendations, integrating international consensus recommendations and the latest domestic evidence across five domains: newborn screening, diagnostic evaluation, levothyroxine treatment, monitoring, and re-evaluation/transition with long-term follow-up.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.